Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, double-blind, controlled study of linaprazan glurate in patients with Gastroesophageal reflux disease (GERD)

Next Previous
Search
Trial Profile

A phase 3 randomized, double-blind, controlled study of linaprazan glurate in patients with Gastroesophageal reflux disease (GERD)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaprazan-glurate (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 24 Sep 2024 According to a Cinclus Pharma media release, planning to initiate the phase III program is underway, with an expected study start in 2025.
    • 29 Jul 2024 According to a Cinclus Pharma media release, recruitment of the first patient is planned for 2025, with the first readout of healing data expected in 2026.
    • 29 Jul 2024 According to a Cinclus Pharma media release, company today announced Swiss-based global company PSI CRO will serve as the clinical research organization for the phase III program of linaprazan glurate, for the treatment of erosive gastroesophageal reflux disease (eGERD).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top